updated 11/11/2010 7:16:44 AM ET 2010-11-11T12:16:44

CHATSWORTH, Calif., Nov. 11, 2010 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory,today announced that Chairman, President and Chief Executive Officer Cesar Garcia, accompanied by other members of senior management, will present an overview of the Company at the 22nd Annual Piper Jaffray Health Care Conference on Tuesday, November 30, 2010 at 1:30 p.m. Eastern time at the New York Palace Hotel in New York City.

Mr. Garcia and senior management will also be available for one-on-one meetings with institutional investors at the conference throughout the day on Tuesday, November 30. Investors interested in scheduling a one-on-one meeting are asked to contact their Piper Jaffray sales rep.

An audio webcast of Mr. Garcia's presentation will be available live and by replay. To access the live audio webcast, go to the investor page of the IRIS website at: http://www.proiris.com/investors/Webcasts_and_Presentations.php , 10 minutes before the webcast is scheduled to begin. The slides accompanying the presentation will also be available on the IRIS website. For those who are unable to listen to the live audio webcast, a replay of the presentation will be archived on the Company's website for 30 days following the conference.

About IRIS International, Inc.

IRIS International, Inc. is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,800 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company recently acquired a high complexity CLIA-certified molecular pathology laboratory offering differentiated, high value molecular diagnostic services in the rapidly growing field of personalized medicine. The laboratory provides a direct commercial channel for the Company's NADiA® ultra-sensitive nucleic acid detection immunoassay platform, with applications in oncology and infectious disease. For more information, please visit www.proiris.com .

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 2.79%
$30K home equity loan FICO 5.78%
$75K home equity loan FICO 4.54%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.57%
13.57%
Cash Back Cards 17.91%
17.91%
Rewards Cards 17.15%
17.15%
Source: Bankrate.com